Related Experiment Video
Updated: Aug 20, 2026

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
Published on: March 28, 2018
Progressive intrahepatic cholestasis: mechanisms, diagnosis and therapy
1Division of Pediatric Hepatology, Mount Sinai School of Medicine, New York, NY 10029, USA. benjamin.shneider@mssm.edu
Insights
Progressive intrahepatic cholestasis (PIHC) is a severe liver disease causing significant health problems and impacting quality of life. Understanding its molecular basis is key to developing effective, disease-specific treatments.
Area of Science:
- Hepatology
- Genetics
- Pediatric Liver Disease
Background:
- Progressive intrahepatic cholestasis (PIHC) encompasses severe inherited liver diseases.
- Characterized by persistent intra-hepatic cholestasis, leading to significant morbidity and mortality.
- Molecular underpinnings of many PIHC forms are increasingly understood.
Purpose of the Study:
- To review the current understanding of progressive intrahepatic cholestasis.
- To highlight the clinical manifestations and complications of PIHC.
- To discuss the need for improved therapeutic strategies.
Main Methods:
- Literature review of recent scientific advances in PIHC.
- Analysis of clinical features and pathological consequences of cholestasis.
- Discussion of current therapeutic limitations.
Main Results:
- PIHC causes profound cholestasis, leading to intractable pruritus and poor quality of life.
- Complications include fat-soluble vitamin malabsorption, osteopenia, bone fractures, xerophthalmia, and neuropathy.
- End-stage liver disease can develop by young adulthood.
Conclusions:
- Optimal therapeutic approaches for PIHC are not well-established.
- Disease-specific treatments are likely required for effective management.
- Further research into molecular mechanisms is crucial for therapeutic development.
Abstract:
Progressive intrahepatic cholestasis (PIHC, also known as progressive familial intrahepatic cholestasis) is a general term encompassing a devastating group of illnesses manifest by severe morbidity and potential mortality. By definition these diseases are characterized by persistent cholestasis that is the result of intra-hepatic rather than extra-hepatic pathology. Recent scientific advances have begun to clarify the molecular basis of many of these disorders. The morbidities of these diseases are primarily the result of profound cholestasis. This cholestasis is often associated with intractable pruritus, which leads to a very poor quality of life. Normal development and sleep are not possible for the affected individual and family dynamics are sometimes irreparably damaged. The cholestasis also leads to complications of fat soluble vitamin malabsorption including osteopenia and pathologic bone fractures, xeropthalmia, and peripheral neuropathy. End-stage liver disease and all of its attendant problems may develop in affected individuals by young adulthood. Optimal therapeutic approaches to PIHC are not well established and disease-specific approaches may be required.
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Chronic Pancreatitis I: Introduction
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Cholecystitis
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Cirrhosis II: Pathophysiology
